ASCO 2023 GI Cancers

CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2023

Expiration: August 28, 2024

Christopher H. Lieu
Christopher H. Lieu, MD
Rachna Shroff
Rachna Shroff, MD, MS, FASCO

Activity

Progress
1
Course Completed

Introduction

In this activity, Christopher H. Lieu, MD, and Rachna T. Shroff, MD, MS, FASCO, review key gastrointestinal (GI) cancer studies presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on new data surrounding the treatment of colorectal, hepatobiliary, and pancreatic cancers.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with GI cancers do you provide care for in a typical month?

A patient with T3 node-negative rectal cancer will receive total mesorectal excision. Based on data from the PROSPECT trial presented at ASCO 2023, how would you counsel this patient regarding neoadjuvant therapy with FOLFOX plus selective chemoradiation vs chemoradiation alone?

Which of the following was reported at ASCO 2023 from the NORPACT-1 phase II trial of upfront surgery vs neoadjuvant FOLFIRINOX followed by surgery for patients with resectable pancreatic head cancers?

Based on data from a phase II basket study presented at ASCO 2023, patients with previously treated advanced biliary tract cancer (BTC) and which of the following HER2 alterations derived benefit from tucatinib plus trastuzumab?